<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573052</url>
  </required_header>
  <id_info>
    <org_study_id>UU40574</org_study_id>
    <nct_id>NCT01573052</nct_id>
  </id_info>
  <brief_title>Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal</brief_title>
  <official_title>Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Salt Lake City Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Salt Lake City Health Care System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind controlled trial comparing treatment outcomes between&#xD;
      chlordiazepoxide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent&#xD;
      veteran subjects. The objective of this trial is to compare the safety and effectiveness of&#xD;
      these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin&#xD;
      over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence,&#xD;
      withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and&#xD;
      alcohol craving.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chlordiazepoxide 25 mg and matching placebo capsules or gabapentin 300 mg and matching&#xD;
      placebo capsules were were used. The chlordiazepoxide/placebo and gabapentin/placebo capsules&#xD;
      were not identical in appearance. Study medications were packaged into a 7-day medication&#xD;
      organizer. The dosing for each subject was either gabapentin 1200mg or chlordiazepoxide 100&#xD;
      mg orally days 1-3, gabapentin 900 mg or chlordiazepoxide 75 mg day 4, gabapentin 600 mg or&#xD;
      chlordiazepoxide 50 mg day 5, and gabapentin 300 mg or chlordiazepoxide 25 mg day 6.&#xD;
&#xD;
      Adherence was assessed by pill counts and serum samples were obtained for study drug&#xD;
      analysis. Serum samples were batched and sent to a contract laboratory so that study&#xD;
      clinicians were blinded to the results until after the trial was completed. Presence of the&#xD;
      assigned study medication in the blood served as a surrogate adherence marker.&#xD;
&#xD;
      Subjects also received prescriptions for daily oral therapeutic multiple vitamin tablets,&#xD;
      folic acid 1 mg, and thiamine 100 mg.&#xD;
&#xD;
      A psychiatric history and physical examination, breath alcohol concentration, vital signs,&#xD;
      CIWA-Ar (alcohol withdrawal scale), and blood chemistry including transaminases and complete&#xD;
      blood cell count were obtained for baseline for all participants. Subjects were seen on&#xD;
      weekdays for clinic follow-up appointments. Assessments performed at each study visit&#xD;
      included CIWA-Ar, ESS (Epworth Sleepiness Scale), PACS (Penn Alcohol Craving Scale), and a&#xD;
      brief examination to document mental status and assess coordination, which included&#xD;
      assessment of stance, tandem gait, Romberg test, pronator drift, toe and heel walk,&#xD;
      rapid-alternating-movements, and point-to-point movements. Breath alcohol concentration (BAC)&#xD;
      was also measured (AlcoSensor, Intoximeters, Inc.) at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>1 week</time_frame>
    <description>ESS is an 8 item-scale and scores range between 0 and 24. The higher the score implies more daytime sleepiness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PENN Alcohol Craving Scale</measure>
    <time_frame>1 week</time_frame>
    <description>PENN is a 5 item self-rated scale of alcohol craving. Scores range from 0 (little craving for alcohol) to 30 (irresistable urge to drink alcohol)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Institute Withdrawal Assessment-Alcohol (Revised)(CIWA-Ar)</measure>
    <time_frame>1 week</time_frame>
    <description>CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Many previously publications suggest a total score of 8-10 is severe enough to warrant medication treatment. Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores &gt; 8 represent more withdrawal symptoms and greater severity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>Chlordiazepoxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlordiazepoxide 25mg capsule or matching placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin 300mg capsule or matching placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlordiazepoxide</intervention_name>
    <description>25mg four times daily x 3 days then tapered over 3 days</description>
    <arm_group_label>Chlordiazepoxide</arm_group_label>
    <other_name>Librium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>300mg four times daily x 3 days then tapered over 3 days</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Alcohol dependent at risk for withdrawal symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Benzodiazepine dependent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher J Stock, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salt Lake VA Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George E Wahlen VA Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <results_first_submitted>December 18, 2012</results_first_submitted>
  <results_first_submitted_qc>August 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2020</results_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Salt Lake City Health Care System</investigator_affiliation>
    <investigator_full_name>Christopher J. Stock, PharmD</investigator_full_name>
    <investigator_title>Investigational pharmacist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlordiazepoxide</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from VA outpatient detoxification clinic</recruitment_details>
      <pre_assignment_details>Exclusions: subjects requiring hospitalization, receiving benzodiazepines prior to randomization and subjects not likely to follow instructions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chlordiazepoxide</title>
          <description>25mg four times daily x 3 days, 25mg three times daily x 1 day, 25mg twice daily x 1 day, 25mg at bedtime x 1 day then discontinue</description>
        </group>
        <group group_id="P2">
          <title>Gabapentin</title>
          <description>300mg four times daily x 3 days, 300mg three times daily x 1 day, 300mg twice daily x 1 day, 300mg at bedtime x 1 day then discontinue</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chlordiazepoxide</title>
          <description>25mg qid x 3 days, 25mg tid x 1 day, 25mg bid x 1 day, 25mg hs x 1 day then d/c</description>
        </group>
        <group group_id="B2">
          <title>Gabapentin</title>
          <description>300mg qid x 3 days, 300mg tid x 1 day, 300mg bid x 1 day, 300mg hs x 1 day then d/c</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="4.8"/>
                    <measurement group_id="B2" value="51.1" spread="7.7"/>
                    <measurement group_id="B3" value="52.7" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Epworth Sleepiness Scale (ESS)</title>
        <description>ESS is an 8 item-scale and scores range between 0 and 24. The higher the score implies more daytime sleepiness.</description>
        <time_frame>1 week</time_frame>
        <population>Late withdrawal period days 5-7</population>
        <group_list>
          <group group_id="O1">
            <title>Chlordiazepoxide</title>
            <description>25mg four times daily x 3 days, 25mg three times daily x 1 day, 25mg twice daily x 1 day, 25mg at bedtime x 1 day then discontinue</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>300mg four times daily x 3 days, 300mg three times daily x 1 day, 300mg twice daily x 1 day, 300mg at bedtime x 1 day then discontinue</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale (ESS)</title>
          <description>ESS is an 8 item-scale and scores range between 0 and 24. The higher the score implies more daytime sleepiness.</description>
          <population>Late withdrawal period days 5-7</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" lower_limit="3.13" upper_limit="9.57"/>
                    <measurement group_id="O2" value="2.65" lower_limit="0.44" upper_limit="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PENN Alcohol Craving Scale</title>
        <description>PENN is a 5 item self-rated scale of alcohol craving. Scores range from 0 (little craving for alcohol) to 30 (irresistable urge to drink alcohol)</description>
        <time_frame>1 week</time_frame>
        <population>Late withdrawal period days 5-7</population>
        <group_list>
          <group group_id="O1">
            <title>Chlordiazepoxide</title>
            <description>25mg four times daily x 3 days, 25mg three times daily x 1 day, 25mg twice daily x 1 day, 25mg at bedtime x 1 day then discontinue</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>300mg four times daily x 3 days, 300mg three times daily x 1 day, 300mg twice daily x 1 day, 300mg at bedtime x 1 day then discontinue</description>
          </group>
        </group_list>
        <measure>
          <title>PENN Alcohol Craving Scale</title>
          <description>PENN is a 5 item self-rated scale of alcohol craving. Scores range from 0 (little craving for alcohol) to 30 (irresistable urge to drink alcohol)</description>
          <population>Late withdrawal period days 5-7</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.78" lower_limit="10.92" upper_limit="22.64"/>
                    <measurement group_id="O2" value="10.74" lower_limit="7.09" upper_limit="14.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Institute Withdrawal Assessment-Alcohol (Revised)(CIWA-Ar)</title>
        <description>CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Many previously publications suggest a total score of 8-10 is severe enough to warrant medication treatment. Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores &gt; 8 represent more withdrawal symptoms and greater severity</description>
        <time_frame>1 week</time_frame>
        <population>Late withdrawal period days 5-7</population>
        <group_list>
          <group group_id="O1">
            <title>Chlordiazepoxide</title>
            <description>25mg four times daily x 3 days, 25mg three times daily x 1 day, 25mg twice daily x 1 day, 25mg at bedtime x 1 day then discontinue</description>
          </group>
          <group group_id="O2">
            <title>Gabapentin</title>
            <description>300mg four times a day x 3 days, 300mg three times daily x 1 day, 300mg twice daily x 1 day, 300mg at bedtime x 1 day then discontinue</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Institute Withdrawal Assessment-Alcohol (Revised)(CIWA-Ar)</title>
          <description>CIWA-Ar measures severity of 10 observed or measured alcohol withdrawal signs or symptoms. Total score ranges from 0 (best possible outcome)-67 (worst possible outcome). Many previously publications suggest a total score of 8-10 is severe enough to warrant medication treatment. Lower scores (0-8) represent fewer withdrawal symptoms and less severity, scores &gt; 8 represent more withdrawal symptoms and greater severity</description>
          <population>Late withdrawal period days 5-7</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" lower_limit="-0.28" upper_limit="6.88"/>
                    <measurement group_id="O2" value="4.33" lower_limit="2.10" upper_limit="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <desc>Daily assessments of mental status, stance, tandem gait, Romberg test, pronator drift, toe and heel walk, rapid-alternating-movements, and point-to-point movements.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chlordiazepoxide</title>
          <description>25mg qid x 3 days, 25mg tid x 1 day, 25mg bid x 1 day, 25mg hs x 1 day then d/c</description>
        </group>
        <group group_id="E2">
          <title>Gabapentin</title>
          <description>300mg qid x 3 days, 300mg tid x 1 day, 300mg bid x 1 day, 300mg hs x 1 day then d/c</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christopher Stock</name_or_title>
      <organization>VA Salt Lake City Medical Center</organization>
      <phone>801-582-1565 ext 1172</phone>
      <email>christopher.stock@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

